KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2025)

Historic Net Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3135.32%.

  • Recursion Pharmaceuticals' Net Margin fell 27678600.0% to 3135.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 1637.81%, marking a year-over-year decrease of 10583000.0%. This contributed to the annual value of 788.02% for FY2024, which is 520300.0% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Net Margin of 3135.32% as of Q3 2025, which was down 27678600.0% from 894.23% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Margin peaked at 367.46% during Q3 2024, and registered a low of 3935.46% during Q4 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' median Net Margin value was 883.1% (recorded in 2023), while the average stood at 1265.34%.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Net Margin skyrocketed by 293818100bps in 2021, and later tumbled by -30815800bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Margin (Quarter) stood at 2564.55% in 2021, then surged by 83bps to 445.91% in 2022, then tumbled by -91bps to 853.88% in 2023, then tumbled by -361bps to 3935.46% in 2024, then rose by 20bps to 3135.32% in 2025.
  • Its Net Margin stands at 3135.32% for Q3 2025, versus 894.23% for Q2 2025 and 1373.26% for Q1 2025.